Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
|---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about Moderna, Inc.
Moderna, Inc. News
Moderna, Inc. Quantitative Score
About Moderna, Inc.
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, human immunodeficiency virus, herpes simplex virus, and varicella-zoster virus vaccines; and public health vaccines consists of Zika and Nipah vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; localized regenerative, systemic intracellular, and inhaled pulmonary therapeutics. It has strategic alliances with AstraZeneca PLC; Merck & Co., Inc.; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Carisma Therapeutics, Inc.; Metagenomi, Inc.; the Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation, as well as a collaboration and license agreement with Chiesi Farmaceutici S.P.A. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Moderna, Inc. Earnings & Revenue
Moderna, Inc. Financials
Table Compare
Compare MRNA metrics with: | |||
|---|---|---|---|
Earnings & Growth | MRNA | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | MRNA | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | MRNA | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | MRNA | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
Moderna, Inc. Income
Moderna, Inc. Balance Sheet
Moderna, Inc. Cash Flow
Moderna, Inc. Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
| Metrics | Score |
|---|---|
| Discounted Cash Flows | Strong Sell |
| Return on Equity | Strong Sell |
| Return on Assets | Strong Sell |
| Debt/Equity Ratio | Neutral |
| Price/Earnings Ratio | Strong Sell |
| Price/Book Ratio | Sell |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Moderna, Inc. Valuation
Project future cash flows and get the intrinsic value per share.
Historical Market Cap
Shares Outstanding
Moderna, Inc. Executives
| Name | Role |
|---|---|
| Mr. Stephane Bancel | Chief Executive Officer & Director |
| Dr. Stephen Hoge M.D. | President |
| Mr. James M. Mock | Chief Financial Officer |
| Ms. Shannon Thyme Klinger | Chief Legal Officer & Corporate Secretary |
| Dr. Melanie Ivarsson M.B.A., Ph.D. | Chief Development Officer |
| Name | Role | Gender | Date of Birth | Pay |
|---|---|---|---|---|
| Mr. Stephane Bancel | Chief Executive Officer & Director | Male | 1973 | 4.55M |
| Dr. Stephen Hoge M.D. | President | 1977 | 1.92M | |
| Mr. James M. Mock | Chief Financial Officer | Male | 1977 | 1.4M |
| Ms. Shannon Thyme Klinger | Chief Legal Officer & Corporate Secretary | Female | 1971 | 1.39M |
| Dr. Melanie Ivarsson M.B.A., Ph.D. | Chief Development Officer | -- |
Moderna, Inc. Insider Trades
| Date | 6 Sep |
| Name | Klinger Shannon Thyme |
| Role | Chief Legal Officer |
| Transaction | Acquired |
| Type | M-Exempt |
| Shares | 1139 |
| Date | 9 Sep |
| Name | Klinger Shannon Thyme |
| Role | Chief Legal Officer |
| Transaction | Disposed |
| Type | S-Sale |
| Shares | 551 |
| Date | 6 Sep |
| Name | Klinger Shannon Thyme |
| Role | Chief Legal Officer |
| Transaction | Disposed |
| Type | M-Exempt |
| Shares | 1139 |
| Date | 30 Aug |
| Name | Klinger Shannon Thyme |
| Role | Chief Legal Officer |
| Transaction | Acquired |
| Type | M-Exempt |
| Shares | 233 |
| Date | 3 Sep |
| Name | Klinger Shannon Thyme |
| Role | Chief Legal Officer |
| Transaction | Disposed |
| Type | S-Sale |
| Shares | 114 |
| Date | Name | Role | Transaction | Type | Shares |
|---|---|---|---|---|---|
| 6 Sep | Klinger Shannon Thyme | Chief Legal Officer | Acquired | M-Exempt | 1139 |
| 9 Sep | Klinger Shannon Thyme | Chief Legal Officer | Disposed | S-Sale | 551 |
| 6 Sep | Klinger Shannon Thyme | Chief Legal Officer | Disposed | M-Exempt | 1139 |
| 30 Aug | Klinger Shannon Thyme | Chief Legal Officer | Acquired | M-Exempt | 233 |
| 3 Sep | Klinger Shannon Thyme | Chief Legal Officer | Disposed | S-Sale | 114 |